Abatacept Intravenous (IV) Powder bulk supplier for pharma manufacturers

Abatacept Intravenous (Iv) Powder 250 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV) Powder

Available Strengths: 250 mg/vial

Reference Brands: Orencia(US & EU)

Category: Arthritis

Abatacept inhibits T-cell activation by blocking CD80/CD86 co-stimulatory signals, reducing inflammation in autoimmune diseases. Benefits include rapid symptom relief, slowed disease progression, improved joint function, and convenient IV administration. It offers effective disease control with a good safety profile when monitored properly.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Abatacept IV powder is approved in both the EU and US for rheumatoid arthritis and other autoimmune diseases. In the EU, brands like Orencia are regulated by EMA, with dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval relies on comprehensive clinical data, biosimilarity assessments, and ongoing pharmacovigilance. Both regions require detailed dossiers for approval and continuous safety monitoring. For expert support with regulatory dossiers, registration, and compliance, visit PharmaTradz. We streamline market access for abatacept IV products, ensuring adherence to European and US standards for safe, effective biologic therapies, helping you navigate complex regulatory landscapes efficiently.

Abatacept Intravenous (Iv) Powder — third party manufacturing & bulk supply

Abatacept Intravenous (Iv) Powder 250 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Abatacept Intravenous (Iv) Powder is supplied as Intravenous (IV) Powder — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Abatacept Intravenous (Iv) Powder listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Abatacept Intravenous (Iv) Powder →

Back to Listing

Frequently Asked Questions

Abatacept is used to treat autoimmune conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. It reduces inflammation and helps prevent joint damage by inhibiting T-cell activation.

Abatacept is a recombinant fusion protein composed of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1. This engineered protein blocks costimulatory signals required for full T-cell activation.

The primary trade name for abatacept is Orencia.

Orencia (abatacept) is marketed by Bristol Myers Squibb.

The generic name is abatacept.

The brand name is Orencia.

Orencia is manufactured in approved Bristol Myers Squibb facilities, primarily in the United States and at additional licensed manufacturing sites in Europe for global supply.